WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...

BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA® (exenatide) injection, which has been available in the U.S. since June 2005 and is used in approximately 60 ...

AstraZeneca has launched in the UK a new pre-filled pen containing its once-weekly diabetes drug Bydureon (exenatide), offering patients a simpler route of administration. AstraZeneca has launched in ...

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...

WILMINGTON, Del., Jan. 10, 2018 /PRNewswire/ -- AstraZeneca today announced that BYDUREON ® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the ...

SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass., Mar 03, 2011 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today ...

WILMINGTON, Del. — AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an ...

BYDUREON BCISE The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes. The Food and Drug ...

New PDUFA Action Date Expected Within 14 Days, per FDA Guidelines SAN DIEGO, INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: ...

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to Bydureon (exenatide 2 mg powder and ...